/PRNewswire/ Luye Pharma Switzerland AG ("Luye Switzerland"), a fully owned subsidiary of Luye Pharma Group (Luye Pharma), and Esteve Pharmaceuticals, S.A..
Global Drug Delivery Systems (DDS) Markets 2021-2027 - Increasing R&D Expenditures of Innovator Companies and the Trend of Patent Portfolio Expansion prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BOSTON, May 13, 2021 /PRNewswire/ The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, took part in the 24
th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company s latest preclinical developments in gene and cell therapy to the global biological community.
ASGCT is one of the world s most influential academic conferences in the area of gene and cell therapy. More than 3,500 scholars, clinical investigators, physicians and other professionals attend the meeting every year. The ASCCT annual meeting is held as a virtual event from May 11 to 14 this year.
Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.